Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LUFYLLIN vs ACCURBRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LUFYLLIN (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway hyperresponsiveness. It also antagonizes adenosine receptors.
Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.
FDA-approved: Relief and prevention of bronchospasm associated with asthma, chronic bronchitis, and emphysema.,Off-label: Apnea of prematurity, COPD exacerbations.
FDA-approved: Treatment of COPD exacerbations,Off-label: Acute asthma exacerbations
200-400 mg orally 3-4 times daily, not to exceed 1600 mg/day. Also available as 200 mg/m L injection, administer 200-400 mg IM or slow IV every 6-8 hours.
Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.
6-8 hours in adults with normal hepatic and renal function. In neonates, half-life is prolonged to 20-30 hours. In patients with hepatic cirrhosis, half-life may extend to 20-30 hours. In congestive heart failure, half-life is prolonged to 12-20 hours.
Terminal elimination half-life: 8-12 hours (healthy adults), prolonged to 15-20 hours in hepatic impairment. Clinical context: Supports twice-daily dosing in most patients.
Dyphylline is not metabolized by the liver; it is primarily excreted unchanged by the kidneys. Approximately 80% is eliminated unchanged in urine.
Ipratropium: minimally metabolized via hydrolysis and conjugation; Albuterol: primarily metabolized by catechol-O-methyltransferase (COMT) and sulfation.
Primarily renal excretion of unchanged drug and metabolites. Approximately 50% is excreted unchanged in urine, with the remainder as metabolites (including 7-hydroxypropyltheophylline and 1,3-dimethyluric acid). Biliary/fecal elimination accounts for <10%.
Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
Approximately 40-50% bound to plasma proteins, primarily albumin.
85-90% bound to albumin.
0.5-0.7 L/kg. This indicates distribution into total body water with some tissue binding.
0.8-1.2 L/kg (wide distribution into tissues, including lungs).
Oral immediate-release: 90-100%. Rectal: approximately 80-90%. Sustained-release: 70-90% with delayed absorption.
Oral: 60-80% (first-pass metabolism reduces bioavailability).
Cr Cl 30-50 m L/min: administer 50-75% of normal dose. Cr Cl <30 m L/min: administer 25-50% of normal dose. Consider monitoring theophylline levels.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing oral dose by 50% or extending interval due to accumulation of acetylcysteine metabolites.
Child-Pugh A: no adjustment. Child-Pugh B: administer 50% of normal dose. Child-Pugh C: avoid use or administer 25% of normal dose with close monitoring.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential increased exposure.
Children <1 year: 100-200 mg/day in 3-4 divided doses. Children 1-9 years: 200-300 mg/day in 3-4 divided doses. Children 9-16 years: 200-400 mg/day in 3-4 divided doses. Weight-based alternative: 10-20 mg/kg/day in 3-4 divided doses.
Inhalation: Infants and children: 1-2 m L of 20% solution or 2-4 m L of 10% solution nebulized three to four times daily. Oral: Not typically recommended for chronic use; for acetaminophen overdose, weight-based dosing is used.
Initiate at lower end of dosing range (200 mg 3 times daily). Monitor theophylline levels and adjust dose to maintain trough concentration of 5-15 mcg/m L. Reduce dose if concurrent medications affecting hepatic metabolism.
No specific dose adjustment; monitor for adverse effects such as bronchospasm or nausea. Use with caution in elderly with renal impairment (refer to renal adjustment).
No FDA black box warning.
No FDA boxed warning exists for this combination product.
Use with caution in patients with peptic ulcer disease, hyperthyroidism, hypertension, cardiac arrhythmias, or seizure disorders. Monitor serum levels for toxicity. Risk of ventricular arrhythmias or seizures at high doses.
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension), worsening of narrow-angle glaucoma, urinary retention, hypokalemia, and immediate hypersensitivity reactions.
Hypersensitivity to dyphylline or any xanthine derivative. Uncontrolled arrhythmias. Active seizure disorder. Severe hypotension. Concurrent use with other xanthines (e.g., theophylline).
Hypersensitivity to ipratropium, albuterol, or atropine; history of anaphylaxis to soya lecithin or related food products; narrow-angle glaucoma; prostatic hyperplasia or bladder neck obstruction (relative).
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase adverse effects like nervousness and palpitations. No significant food interactions other than caffeine. Alcohol may increase CNS stimulation.
High-fat meals can increase absorption of theophylline; take on an empty stomach or with light snack for consistent effect. Avoid large amounts of charcoal-broiled foods as they may decrease drug levels. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) can potentiate side effects such as nervousness, tremor, and insomnia. Charbroiled meats and cruciferous vegetables (broccoli, Brussels sprouts) may induce metabolism and reduce effectiveness. Grapefruit juice may increase theophylline levels; avoid concurrent use.
Lufyllin (dyphylline) is a xanthine derivative bronchodilator. Animal studies have not demonstrated teratogenicity. Human data are limited; however, as a methylxanthine, risks are considered low. First trimester: No evidence of major malformations. Second and third trimesters: No known fetal harm, but high doses may cause transient neonatal tachycardia or irritability due to placental transfer. Avoid use near term if possible due to potential neonatal effects.
No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.
Dyphylline is excreted into breast milk in small amounts. The milk-to-plasma ratio is approximately 0.7. Estimated infant dose is about 1-2% of maternal weight-adjusted dose. No adverse effects reported in breastfed infants. However, monitor for signs of irritability or sleep disturbances.
Not known if excreted in human breast milk. Caution advised; consider developmental benefits vs risks. M/P ratio not available.
Pregnancy may alter the pharmacokinetics of methylxanthines due to increased plasma volume and decreased protein binding. However, dyphylline is not extensively protein-bound, so changes may be minimal. No specific dose adjustment is recommended, but monitor clinical response and toxicity. Avoid doses exceeding standard recommendations.
No dose adjustment routinely recommended; however, increased clearance may require monitoring for therapeutic effect.
Dyphylline (Lufyllin) is a xanthine bronchodilator that is not metabolized to theophylline, making it an alternative for patients who cannot tolerate theophylline. It is 2-3 times less potent than theophylline, requiring higher doses. Renal excretion is the primary elimination route; dose adjustment is needed in renal impairment. Monitor drug interactions with cimetidine, quinolones, and macrolides, though less severe than with theophylline. Use with caution in patients with peptic ulcer, hyperthyroidism, or seizure disorders. Therapeutic levels are not well-defined, but target 6-18 mcg/m L for theophylline equivalents.
Accurbron (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L. Hepatic metabolism is highly variable; monitor levels closely in patients with liver impairment, heart failure, or those on interacting drugs. Smoking induces metabolism, requiring higher doses. Use with caution in elderly and patients with seizure disorders or peptic ulcer disease. Do not crush or chew extended-release tablets.
Take this medication exactly as prescribed, do not double doses if missed.,Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may increase side effects.,Report any signs of toxicity such as nausea, vomiting, insomnia, anxiety, or palpitations.,Do not crush or chew extended-release tablets unless instructed.,Maintain adequate hydration to help prevent side effects.,Inform your doctor if you are pregnant, breastfeeding, or have liver, kidney, or heart disease.
Take exactly as prescribed; do not change dose without doctor approval.,Do not crush or chew sustained-release tablets.,Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report any symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, seizures.,Smoking or quitting smoking can affect theophylline levels; inform your doctor about any changes in smoking habits.,Keep regular appointments for blood tests to monitor drug levels.,Avoid taking other medications, including over-the-counter drugs and herbal supplements, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LUFYLLIN vs ACCURBRON, answered by our medical review team.
LUFYLLIN is a Xanthine Bronchodilator that works by LUFYLLIN (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway hyperresponsiveness. It also antagonizes adenosine receptors.. ACCURBRON is a Methylxanthine Bronchodilator that works by Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LUFYLLIN and ACCURBRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LUFYLLIN is: 200-400 mg orally 3-4 times daily, not to exceed 1600 mg/day. Also available as 200 mg/m L injection, administer 200-400 mg IM or slow IV every 6-8 hours.. The standard adult dose of ACCURBRON is: Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LUFYLLIN and ACCURBRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LUFYLLIN is classified as Category C. Lufyllin (dyphylline) is a xanthine derivative bronchodilator. Animal studies have not demonstrated teratogenicity. Human data are limited; however, as a methylxanthine, risks are . ACCURBRON is classified as Category C. No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.